AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Report Publication Announcement Jul 12, 2024

7612_rns_2024-07-12_d50fc694-701f-40e8-b9fb-250394ddc2a4.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 2144W

Eco Animal Health Group PLC

12 July 2024

12 July 2024

A green and white sign with black text Description automatically generated

ECO Animal Health Group plc

(''ECO" or the "Company")

Investor Presentation covering Full Year Results

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's Full Year results for the period ended 31 March 2024.

The online presentation will take place on Tuesday 16 July at 16:00 BST. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.

To register for the event, please click here .  

A video recording of the presentation will be available shortly afterwards   here .

Contacts:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)
020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Lydia Zychowska
020 7597 5970
Equity Development

Hannah Crowe

Matt Evans
020 7065 2692
ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson
020 3709 5700

[email protected]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information:  https://ecoanimalhealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPUWAMUPCUMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.